White Paper — Sponsored Content

Manufacturing a Cure for the World’s Most Devastating Diseases

Azzur Group

At the rate that innovation is coming to the cell and gene therapy space, this is undoubtedly an exciting time for the industry to extend its reach to patients. And, as the technologies become more advanced and transform, regulations are going to evolve and adapt in order to address the biggest risks to the patient. As you look to implement GxP approaches to CGT manufacturing, it's important to understand current regulatory standards for pharmaceuticals and biotechnology, as well as how they translate to novel therapeutics. From regulatory guidance to infrastructure to training, there are a myriad of challenges for cell and gene therapy (CGT) innovators. Download this white paper to learn more about how to navigate these hurdles in bringing your treatment to market.

Whitepaper Download

Download White Paper


To download this white paper, complete the form below. Once submitted, you will receive a link via the email you provided to download the white paper.

Name
Company Type
Address

By completing this form, you consent to have your information provided to the third-party sponsor of this content and may use your information to provide information about relevant products, services, and other opportunities which may be of interest to you . ISPE will store your information in a secure environment and may use your information to provide information about relevant products, services, and other opportunities which may be of interest to you. You may unsubscribe from these ISPE communications at any time. For more information or to unsubscribe, review our Privacy Policy or contact us at ask@ispe.org.